华北制药：关于“提质增效重回报”行动方案的公告

Core Viewpoint - North China Pharmaceutical has announced a "Quality Improvement and Efficiency Enhancement Return" action plan aimed at enhancing operational quality, shareholder returns, and fostering technological innovation [1] Group 1: Action Plan Highlights - The company will focus on its core business to improve operational quality [1] - Emphasis will be placed on shareholder returns, with a commitment to distribute no less than 30% of annual distributable profits as cash dividends [1] - The plan includes strengthening investor relations management to enhance value transmission [1] Group 2: Financial Commitments - Over the past three years, the company has distributed a total of 68.6292 million yuan in dividends [1] - Cumulative investment in research and development over three years amounts to approximately 3.7 billion yuan [1] Group 3: Governance and Management - The company aims to improve governance standards and operational compliance [1] - There will be a focus on managing the "key minority" to solidify responsibility in performance [1]